These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 23957062)

  • 1. [III. Molecular targeting therapy for glioma-bevacizumab and cilengitide].
    Kurozumi K; Onishi M; Ichikawa T; Fujii K; Ishida J; Shimazu Y; Date I
    Gan To Kagaku Ryoho; 2013 Jun; 40(6):718-22. PubMed ID: 23957062
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiogenesis and invasion in glioma.
    Onishi M; Ichikawa T; Kurozumi K; Date I
    Brain Tumor Pathol; 2011 Feb; 28(1):13-24. PubMed ID: 21221826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Molecular-Targeted Drug Therapy for Glioma Angiogenesis and Invasion].
    Kurozumi K; Date I
    No Shinkei Geka; 2015 Aug; 43(8):691-701. PubMed ID: 26224462
    [No Abstract]   [Full Text] [Related]  

  • 4. Recurrent high-grade glioma: a diagnostic and therapeutic challenge.
    Walbert T; Mikkelsen T
    Expert Rev Neurother; 2011 Apr; 11(4):509-18. PubMed ID: 21469924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cilengitide treatment for malignant glioma: current status and future direction.
    Kurozumi K; Ichikawa T; Onishi M; Fujii K; Date I
    Neurol Med Chir (Tokyo); 2012; 52(8):539-47. PubMed ID: 22976135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cilengitide in bevacizumab-refractory high-grade glioma: two case reports and critical review of the literature.
    Lombardi G; Zustovich F; Farina P; Polo V; Farina M; Della Puppa A; Bertorelle R; Gardiman MP; Berti F; Zagonel V
    Anticancer Drugs; 2012 Aug; 23(7):749-53. PubMed ID: 22382388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular biomarker-guided anti-angiogenic targeted therapy for malignant glioma.
    Yan C; Wang J; Yang Y; Ma W; Chen X
    J Cell Mol Med; 2019 Aug; 23(8):4876-4882. PubMed ID: 31210419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models.
    Onishi M; Ichikawa T; Kurozumi K; Fujii K; Yoshida K; Inoue S; Michiue H; Chiocca EA; Kaur B; Date I
    Neuropathology; 2013 Apr; 33(2):162-74. PubMed ID: 22989076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cilengitide Merck.
    Smith JW
    Curr Opin Investig Drugs; 2003 Jun; 4(6):741-5. PubMed ID: 12901235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trials referral resource. Current clinical trials of cilengitide, an alpha(v) antagonist in clinical development as an anticancer agent.
    Colevas AD; Scharf O; Schoenfeldt M
    Oncology (Williston Park); 2004 Dec; 18(14):1778, 1781-2, 1784. PubMed ID: 15700626
    [No Abstract]   [Full Text] [Related]  

  • 11. [Cancer metastasis-related molecules and their targeted drugs].
    Takagi S; Fujita N
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():159-63. PubMed ID: 23513831
    [No Abstract]   [Full Text] [Related]  

  • 12. Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma.
    Guillot A; Levy A; Pacaut C; Collard O; Massard C; Merrouche Y; Magné N
    Clin Genitourin Cancer; 2012 Sep; 10(3):147-52. PubMed ID: 22796529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pep-1 peptide-functionalized liposome to enhance the anticancer efficacy of cilengitide in glioma treatment.
    Jiao Z; Li Y; Pang H; Zheng Y; Zhao Y
    Colloids Surf B Biointerfaces; 2017 Oct; 158():68-75. PubMed ID: 28672205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7 T.
    Grabner G; Nöbauer I; Elandt K; Kronnerwetter C; Woehrer A; Marosi C; Prayer D; Trattnig S; Preusser M
    Magn Reson Imaging; 2012 Jan; 30(1):139-47. PubMed ID: 21982163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab in the treatment of high-grade gliomas: an overview.
    Kunnakkat S; Narayana A
    Angiogenesis; 2011 Dec; 14(4):423-30. PubMed ID: 21858651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cilengitide: does it really represent a new targeted therapy for recurrent glioblastoma?
    Chamberlain MC
    J Clin Oncol; 2009 Apr; 27(11):1921; author reply 1922. PubMed ID: 19255301
    [No Abstract]   [Full Text] [Related]  

  • 17. Bevacizumab as salvage therapy for progressive brain stem gliomas.
    Reithmeier T; Lopez WO; Spehl TS; Nguyen T; Mader I; Nikkhah G; Pinsker MO
    Clin Neurol Neurosurg; 2013 Feb; 115(2):165-9. PubMed ID: 22652237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advantages of high b-value diffusion-weighted imaging to diagnose pseudo-responses in patients with recurrent glioma after bevacizumab treatment.
    Yamasaki F; Kurisu K; Aoki T; Yamanaka M; Kajiwara Y; Watanabe Y; Takayasu T; Akiyama Y; Sugiyama K
    Eur J Radiol; 2012 Oct; 81(10):2805-10. PubMed ID: 22100373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Bevacizumab for neurological complications during initial treatment of malignant gliomas.
    Arratibel-Echarren I; Albright K; Dalmau J; Rosenfeld MR
    Neurologia; 2011 Mar; 26(2):74-80. PubMed ID: 21163238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas.
    Chamberlain MC
    Cancer; 2010 Sep; 116(17):3988-99. PubMed ID: 20564141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.